Search Results

You are looking at 11 - 20 of 290 items for :

  • "neutropenia" x
Clear All
Full access

Demetrios N. Kyriacou, Borko Jovanovic and Olga Frankfurt

several studies that illustrate the delayed times to initial antibiotic treatment for adults with FN in EDs Table 1 Current Guidelines for Timing of Initial Antibiotic Treatment of Adult Patients With Febrile Neutropenia worldwide, indicating

Full access

Betsy L. Althaus

-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumors . Eur J Cancer 2006 ; 42 : 2433 – 2453 . 8. Scott SD Chrischilles EA Link BK . Days of prophylactic

Full access

Yanli Li, Leila Family, Su-Jau Yang, Zandra Klippel, John H. Page and Chun Chao

Background Febrile neutropenia (FN) is a serious adverse effect of myelosuppressive chemotherapy that can affect treatment by contributing to dose delays and reductions. 1 FN often requires hospitalization and incurs a significant healthcare

Full access

Deborah S. Yolin-Raley, Ibiayi Dagogo-Jack, Heidi B. Niell, Robert J. Soiffer, Joseph H. Antin, Edwin P. Alyea III and Brett E. Glotzbecker

Background Most patients treated with myeloablative conditioning regimens before hematopoietic stem cell transplantation (HSCT) develop neutropenic fevers in the pre-engraftment period because of profound neutropenia. 1 , 2 Fevers may signify

Full access

Leila Family, Yanli Li, Lie Hong Chen, John H. Page, Zandra K. Klippel and Chun Chao

Risk of developing chemotherapy-induced febrile neutropenia (FN) depends on patient-, treatment-, and disease-related characteristics. 1 In our prior investigation, several chronic comorbidities were associated with significantly increased FN

Full access

Sriman Swarup, Anita Sultan, Somedeb Ball, Francis Mogollon-Duffo, Nimesh Adhikari, Yin M. Myat, Myo H. Zaw, Catherine Jones and Kyaw Z. Thein

: MEDLINE, EMBASE databases, and meeting abstracts from inception through September 2018 were queried. RCTs that mention anemia, thrombocytopenia, leukopenia, neutropenia, and neutropenic fever as adverse effects were incorporated in the analysis. Mantel

Full access

Gary H. Lyman

a prospective nationwide study of oncology practice . J Natl Compr Canc Netw 2008 ; 6 : 109 – 118 . 2 Kuderer NM Dale DC Crawford J . Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients . Cancer

Full access

Substantial improvements have occurred in the management of infectious disease in patients with cancer. It is now unusual for patients with acute leukemia who receive their initial induction chemotherapy at a major center to die of infectious complications. Many patients will undergo further therapy that leads to prolonged periods of neutropenia without succumbing to a major infectious complication. However, managing infections in neutropenic patients remains a dynamic process, affected by the appearance of new pathogens, the emergence of antibiotic-resistant organisms, and the improved stratification of patients' infection risk. All of these factors have fostered new treatment approaches. These NCCN clinical guidelines address many of the day-to-day issues inherent in managing fever and neutropenia.

For the most recent version of the guidelines, please visit

Full access

Derek Weycker, Xiaoyan Li, Rich Barron, Hongsheng Wu, P.K. Morrow, Hairong Xu, Maureen Reiner, Jacob Garcia, Shivani K. Mhatre and Gary H. Lyman

Background Neutropenia is a common side effect of myelosuppressive chemotherapy that increases the risk of infection, which is typically signaled by fever. When neutropenic patients develop fever (ie, febrile neutropenia [FN]), the likelihood

Full access

Jeffrey Crawford, Jeffrey Allen, James Armitage, Douglas W. Blayney, Spero R. Cataland, Mark L. Heaney, Sally Htoy, Susan Hudock, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Brandon McMahon, David P. Steensma, Saroj Vadhan-Raj, Peter Westervelt and Michael Westmoreland

Overview Neutropenia (< 500 neutrophils/mcL or < 1000 neutrophils/mcL and a predicted decline to < 500/mcL over the next 48 hours) and resulting febrile neutropenia (≥ 38.3°C orally or ≥ 38.0°C over 1 hour) can be induced by myelosuppressive